A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Clinical trial NCT04225156 · COMPLETED

Trial details

NCT number: NCT04225156
Sponsor: argenx
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Immune Thrombocytopenia

Start date: 2020-06-02
Primary completion: 2026-03-11
Enrollment: 101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.